Table 2 Minimal erythema dose and urine urolithin A glucuronide and dimethylellagic acid glucuronide in UA producers and non producers consuming PomJ, PomX or placebo.

From: Pomegranate Juice and Extract Consumption Increases the Resistance to UVB-induced Erythema and Changes the Skin Microbiome in Healthy Women: a Randomized Controlled Trial

 

Pom Juice UA producer (n = 16)

Pom Juice nonUA producer (n = 8)

Pom extract UA producer (n = 19)

Pom extract nonUA producer (n = 4)

Placebo (n = 25)

Urine UAG (ng/mL)

3147 ± 1861

0

4068 ± 2049

0

n/a

Urine DMEAG (ng/mL)

163 ± 147

199 ± 118

210 ± 155

200 ± 101

n/a

MED BL (mJ/cm2)

385.7 ± 97.7

379.3 ± 100.1

409.2 ± 80.6

347.5 ± 111.4

384.2 ± 105.6

MED F (mJ/cm2)

417.5 ± 126.6

420.0 ± 87.6

440.0 ± 88.1*

373.8 ± 41.1

367.2 ± 90.2

  1. Data are mean ± SD, n = 24–25. ANCOVA model was used to compare outcomes adjusted for baseline value between placebo and Pom extract or placebo and Pom Juice groups; *p < 0.05. Urolithin A glucuronide (UAG); dimethylellagic acid glucuronide (DMEAG); minimal erythema dose (MED); baseline BL; final (F).
Back to article page